Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Jane Elliott AM & Prof Rod Baber AM

Dr Jane Elliott AM & Prof Rod Baber AM

Non-Hormonal Options for Menopausal Symptoms

Prof Rukshen Weerasooriya

Prof Rukshen Weerasooriya

Holter Monitoring in GP – Cases and Practical Tips

Dr Rupert Hinds

Dr Rupert Hinds

Management of Constipation in Children

A/Prof Greg Katsoulotos

A/Prof Greg Katsoulotos

Inhaler Devices – Common User Errors

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023